FlandersBio offers an up-to-date life sciences database with detailed information about all FlandersBio members.
FlandersBio beschikt over een geüpdate life sciences databank met een gedetailleerd overzicht van alle FlandersBio-ledenbedrijven.
Amakem is a kinase platform company focusing on ophthalmology and is developing new treatments for serious eye conditions. The Company's lead candidate, AMA0076, targets glaucoma, a condition which damages the optic nerve resulting in vision loss and ultimately blindness.
Amakem's product pipeline is based on its unique 'Localized Drug Action' platform which generates novel kinase inhibitors that minimize systemic exposure with the aim of reducing side effects.
Amakem is a kinase platform company focusing on ophthalmology and is developing new treatments for serious eye conditions. Amakem’s product pipeline is based on its unique ‘Localized Drug Action’ platform which is designed to generate safe and effective novel kinase inhibitors that minimize systemic exposure with the aim of reducing side effects.
Amakem’s lead candidate, AMA0076, is a novel, highly potent Rho Kinase (ROCK) inhibitor targeted at the treatment of glaucoma, a condition which damages the optic nerve resulting in vision loss and ultimately blindness. AMA0076 has been shown in a number of in vivo models to be highly effective in reducing intraocular pressure (IOP), a major factor in glaucoma, while avoiding hyperemia. Also known as ‘red eye’, hyperemia results from excess blood flow in vessels in the white of the eye. It is a distressing and dose limiting side effect for patients that has hindered the progress of many otherwise promising glaucoma drugs.
Amakem is working to apply the ‘Localized Drug Action’ platform to a range of other eye diseases and has also demonstrated proof-of-concept for the technology in COPD (Chronic Obstructive Pulmonary Disease) and asthma.
Amakem is based in Belgium and located in the life sciences incubator “BioVille” at the University of Hasselt.
Amakem was founded to continue the development of its unique, locally acting kinase inhibitor concept (localized drug action) that the founders embarked upon during their Devgen tenure.
Amakem is developing locally acting small molecule drugs for major chronic diseases such as glaucoma, allergic asthma and chronic obstructive pulmonary disease (COPD). The company’s focus is on ROCK inhibitors for their smooth muscle relaxation and anti-inflammatory effects. Our pipeline, as well as information about the proprietary platform underlying the locally active kinase inhibitors can be discussed under confidentiality.